Annexon
So. San Francisco, US · 4 known investors
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.
BiotechHealthtech
Founders & leadership
DL
Douglas LoveinFounder · President & CEO
ML
Mark L SmithExecutive
CM
Campbell MurrayNamed on SEC filing
TW
Thomas WiggansNamed on SEC filing
RS
TY
Ted YednockNamed on SEC filing
WY
William YoungNamed on SEC filing
BB
Ben BarresScientific Co-Founder
Board
EC
Emmett CunninghamBoard director
MS
Muneer SatterBoard director
CG
Carol GallagherBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$277.5M disclosed across 3 rounds · 2018–2022
▶$130.5MraisedJul 2022 · 12 investors · BiotechnologyRule 506(b)
▶$130.5MraisedJul 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William D. WaddillDirector
- Thomas G. WiggansDirector
- Muneer A. SatterDirector
- Michael OverdorfExecutive Officer
- Larry C. Mattheakis, Ph.DExecutive Officer
- Douglas LoveExecutive Officer, Director
- Jennifer LewExecutive Officer
- Bettina M. Cockroft, M.D.Director
- William H. Carson, M.D.Director
- Jung E. ChoiDirector
- Offering amount
- $130.5M
- Amount sold
- $130.5M
- Sales commissions
- $6.7M
- Placement agents
- Jefferies LLC, Cowen and Company, LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$102MraisedJul 2020 · 17 investors · BiotechnologyRule 506(b)
▶$102MraisedJul 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ted YednockExecutive Officer
- Jung E. ChoiDirector
- William D. YoungDirector
- Emmett CunninghamDirector
- Thomas G. WiggansDirector
- Carol GallagherDirector
- Muneer A. SatterDirector
- Campbell MurrayDirector
- Sanjay KeswaniExecutive Officer
- Jennifer LewExecutive Officer
- Douglas LoveExecutive Officer, Director
- Ricky SunDirector
- Offering amount
- $102M
- Amount sold
- $102M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedDec 2018 · 10 investors · BiotechnologyRule 506(b)
▶$45MraisedDec 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Campbell MurrayDirector
- Douglas LoveExecutive Officer, Director
- Thomas WiggansDirector
- Emmett CunninghamDirector
- Ricky SunDirector
- Muneer SatterDirector
- Carol GallagherDirector
- Ted YednockExecutive Officer
- William YoungDirector
- Mark L SmithExecutive Officer
- Offering amount
- $85M
- Amount sold
- $45M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Annexon do?
- Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.
- Who founded Annexon?
- Annexon was founded by Douglas Love.
- Who are Annexon's investors?
- Annexon's investors include Bain Capital Life Sciences, Correlation Ventures, New Enterprise Associates (NEA), Clarus.
- How much funding has Annexon raised?
- Annexon has disclosed $277.5M raised across 3 rounds.
- Where is Annexon headquartered?
- Annexon is headquartered in So. San Francisco, US.